| Literature DB >> 29599929 |
Jun Shi1, Weidong Leng1, Lunhua Zhao2, Cai Deng1, Chenli Xu2, Jue Wang2, Yu Wang3, Xingchun Peng2,3,4.
Abstract
Conflicting results to identify the relationship between tooth loss and cancer risk. Therefore, a dose-response meta-analysis was performed to clarify and quantitative assessed the correlation between tooth loss and cancer risk. Up to March 2017, 25 observational epidemiological studies were included in current meta-analysis. Tooth loss was significantly associated with a higher risk of cancer. Additionally, tooth loss was associated with significantly a higher risk of esophageal cancer, gastric cancer, head and neck cancer, colorectal cancer, pancreas cancer, lung cancer, prostate cancer, bladder cancer and hematopoietic cancer. Subgroup analysis showed consistent findings. Furthermore, a significant dose-response relationship was observed between tooth loss and cancer risk. Increasing per 10 of tooth loss was associated with a 9% increment of cancer risk, 14% increment of esophageal cancer risk, 9% increment of gastric cancer risk, 31% increment of head and neck cancer risk, 4% increment of colorectal cancer risk, 7% increment of pancreas cancer risk, 19% increment of lung cancer risk, 2% increment of bladder cancer risk and 3% increment of hematopoietic cancer risk. Considering these promising results, tooth loss might be harmful for health. Large sample size, different ethnic population and different cancer type are warranted to validate this association.Entities:
Keywords: cancer; dose–response relationship; meta analysis; tooth loss
Year: 2017 PMID: 29599929 PMCID: PMC5871100 DOI: 10.18632/oncotarget.23850
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Flow diagram of the study selection process
Characteristics of participants in included studies of tooth loss in relation to risk of cancer
| Author (year) | Study design | Country | Sex of population | Age at baseline (years) | No of participants | Endpoints (cases) | Quality score |
|---|---|---|---|---|---|---|---|
| Abnet et al. (2001) | cohort | China | Mix | 40–69 | 29548 | Esophageal cancer (620) | 8 |
| Abnet et al. (2005) | cohort | Finnish | Mix | 50–69 | 29124 | Esophageal cancer (49) | 8 |
| Abnet et al. (2008) | case-control | Iran | Mix | > 18 | 843 | Esophageal cancer (283) | 6 |
| Dar et al. (2013) | case-control | Kashmir | Mix | 61.6 | 2367 | Esophageal cancer (703) | 6 |
| Dye et al. (2007) | case-control | China | Mix | 40–67 | 977500 | Esophageal cancer (579) | 6 |
| Guha et al. (2007) | case-control | USA and Europe | Mix | any age | Europe (4110) | Europe: | 7 |
| Hiraki et al. (2008) | case-control | Japan | Mix | 58.0 | 15720 | Head and neck (429) | 7 |
| Michaud et al. (2008) | cohort | USA | Male | 40–75 | 48375 | Total (5720) | 8 |
| Michaud et al. (2007) | cohort | USA | Male | 40–75 | 51529 | Pancreatic (216) | 8 |
| Shakeri et al. (2013) | case-control | Iran | Mix | 40–75 | 922 | Gastric (588) | 6 |
| Balaram et al. (2002) | case-control | India | Mix | 22–58 | 1164 | oral cavity (584) | 5 |
| Bundgaard et al. (1995) | case-control | Denmark | Mix | < 75 | 559 | oral cavity (161) | 6 |
| Garrote et al. (2001) | case-control | Cuba | Mix | 60 | 400 | oral cavity (200) | 5 |
| Lissowska et al. (2003) | case-control | Poland | Mix | 23–80 | 244 | oral cancer (122) | 6 |
| Talamini et al. (2000) | case-control | Italian | Mix | 27–86 | 274 | oral cancer (131) | 6 |
| Stolzenberg-Solomon et al. (2003) | cohort | Finland | Male | 50–69 | 29104 | pancreatic cancer (174) | 8 |
| Bertrand et al. (2017) | cohort | USA | Male | 40–75 | 51529 | NonHodgkin lymphoma (875) | 8 |
| Chen et al. (2016) | case-control | China | Female | 20–80 | 1246 | Oral cancer (250) | 6 |
| Chen et al. (2016) | case-control | China | Mix | 40–85 | 1386 | Esophagus (616) | 6 |
| Zuo et al. (2014) | case-control | China | Mix | > 18 | 317 | Oral cancer (150) | 7 |
| Divaris et al. (2010) | case-control | USA | Mix | 26–80 | 2650 | Head and Neck Cancer (1361) | 6 |
| Liu et al. (2016) | case-control | China | Mix | 20–74 | 5124 | nasopharyngeal carcinoma (2528) | 6 |
| Momen-Heravi et al. (2017) | cohort | USA | Female | 39–55 | 77443 | colorectal cancer (1165) | 8 |
| Ren et al. (2016) | case-control | China | Mix | 40–79 | 6619 | colorectal cancer (1063) | 6 |
| Huang et al. (2016) | cohort | Sweden | Mix | 20–70 | 19924 | pancreatic cancer (126) | 8 |
Stratified analyses of relative risk of cancer
| No of reports | Relative risk (95% CI) | P for heterogeneity | I2 | P for test | |
|---|---|---|---|---|---|
| Total | 81 | 1.06 (1.02–1.09) | 0.000 | 51.2% | < 0.001 |
| Subgroup analyses for cancer | |||||
| Esophageal cancer | 10 | 1.18 (1.04–1.31) | 0.558 | 0.0% | < 0.001 |
| Subgroup analyses for Esophageal cancer | |||||
| Study location | |||||
| Caucasia | 6 | 1.12 (1.02–1.21) | 0.520 | 0.0% | < 0.001 |
| Asia | 4 | 1.26 (1.08–1.44) | 0.363 | 5.9% | < 0.001 |
| Study design | |||||
| Case–control | 7 | 1.34 (1.04–1.64) | 0.736 | 0.0% | < 0.001 |
| Cohort | 3 | 1.11 (1.04–1.18) | 0.460 | 0.0% | < 0.001 |
| Study quality | |||||
| Score ≥ 7 | 3 | 1.11 (1.04–1.18) | 0.460 | 0.0% | < 0.001 |
| Score < 7 | 7 | 1.34 (1.04–1.64) | 0.736 | 0.0% | < 0.001 |
| Gastric cancer | 9 | 1.09 (1.03–1.16) | 0.763 | 0.0% | < 0.001 |
| Subgroup analyses for Gastric cancer | |||||
| Study location | |||||
| Caucasia | 6 | 1.25 (1.11–1.36) | 0.737 | 0.0% | < 0.001 |
| Asia | 3 | 1.04 (1.01–1.09) | 0.863 | 0.0% | < 0.001 |
| Study design | |||||
| Case–control | 4 | 1.10 (1.02–1.19) | 0.739 | 0.0% | < 0.001 |
| Cohort | 5 | 1.13 (1.04–1.23) | 0.474 | 0.0% | < 0.001 |
| Study quality | |||||
| Score ≥ 7 | 5 | 1.13 (1.04–1.23) | 0.474 | 0.0% | < 0.001 |
| Score < 7 | 4 | 1.10 (1.02–1.19) | 0.739 | 0.0% | < 0.001 |
| Head and neck cancer | 19 | 1.52 (1.14–1.90) | 0.000 | 71.3% | < 0.001 |
| Subgroup analyses for Head and neck cancer | |||||
| Oral cancer | 15 | 1.80 (1.30–2.30) | 0.000 | 67.7% | < 0.001 |
| Pharynx | 2 | 1.14 (1.05–1.23) | 0.295 | 5.7% | < 0.001 |
| Larynx cancer | 2 | 1.08 (1.02–1.15) | 0.004 | 87.5% | < 0.001 |
| Study location | |||||
| Caucasia | 11 | 1.15 (1.04–1.26) | 0.004 | 61.2% | < 0.001 |
| Asia | 8 | 1.82 (1.52–2.12) | 0.288 | 18.6% | < 0.001 |
| Study design | |||||
| Case–control | 18 | 1.52 (1.13–1.92) | 0.000 | 72.7% | < 0.001 |
| Cohort | 1 | 1.60 (0.84–3.04) | 0.288 | 18.6% | 0.121 |
| Study quality | |||||
| Score ≥ 7 | 9 | 1.13 (1.04–1.23) | 0.001 | 70.1% | < 0.001 |
| Score < 7 | 10 | 1.91 (1.58–2.24) | 0.171 | 29.8% | < 0.001 |
| Colorectal cancer | 13 | 1.07 (1.02–1.14) | 0.114 | 33.5% | < 0.001 |
| Subgroup analyses for Colorectal cancer | |||||
| Colon | 5 | 1.09 (1.02–1.17) | 0.330 | 13.2% | < 0.001 |
| Rectal | 3 | 1.08 (1.01–1.17) | 0.082 | 60.0% | < 0.001 |
| Study location | |||||
| Caucasia | 6 | 1.17 (1.07–1.27) | 0.692 | 0.0% | < 0.001 |
| Asia | 7 | 1.05 (1.01–1.09) | 0.986 | 0.0% | < 0.001 |
| Study design | |||||
| Case–control | 7 | 1.05 (1.01–1.09) | 0.986 | 0.0% | < 0.001 |
| Cohort | 6 | 1.17 (1.07–1.27) | 0.692 | 0.0% | < 0.001 |
| Study quality | |||||
| Score ≥ 7 | 7 | 1.16 (1.06–1.25) | 0.669 | 0.0% | < 0.001 |
| Score < 7 | 6 | 0.84 (0.65–1.03) | 0.970 | 0.0% | 0.316 |
| Pancreas cancer | 5 | 1.15 (1.05–1.19) | 0.498 | 0.0% | < 0.001 |
| Lung cancer | 2 | 1.66 (1.34–1.97) | 0.660 | 0.0% | < 0.001 |
| Prostate cancer | 2 | 1.14 (1.03–1.25) | 0.481 | 0.0% | < 0.001 |
| Bladder cancer | 2 | 1.23 (1.12–1.35) | 0.596 | 0.0% | < 0.001 |
| Hematopoietic cancer | 9 | 1.07 (1.02–1.13) | 0.443 | 0.0% | < 0.001 |
Figure 2Dose-response relationship between tooth loss in relation to risk of overall cancer
Figure 3Dose-response relationship between tooth loss in relation to risk of cancer
(A) Colorectal cancer. (B) Esophageal cancer. (C) Gastric cancer. (D) Head and neck cancer.
Figure 4Dose-response relationship between tooth loss in relation to risk of cancer
(A) Bladder cancer. (B) Hematopoietic cancer. (C) Lung cancer. (D) Pancreas cancer.